Carl Zeiss Meditec AG (XSWX:AFX) Cash Flow from Investing: CHF-68 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
75 GF Score
Price CHF29.80
GF Value CHF68.89
! 3 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Cash Flow from Investing?

Carl Zeiss Meditec AG XSWX:AFX 75 Cash Flow from Investing is CHF-68 Mil as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 75/100 and a GF Value™ of CHF68.89. The stock has 3 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2025, Carl Zeiss Meditec AG spent CHF0 Mil on purchasing property, plant, equipment. It gained CHF0 Mil from selling property, plant, and equipment. It spent CHF0 Mil on purchasing business. It gained CHF0 Mil from selling business. It spent CHF0 Mil on purchasing investments. It gained CHF0 Mil from selling investments. It paid CHF0Mil for net Intangibles purchase and sale. And it paid CHF0 Mil for other investing activities. In all, Carl Zeiss Meditec AG gained CHF1 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2025.


Carl Zeiss Meditec AG  (XSWX:AFX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Carl Zeiss Meditec AG's purchase of property, plant, equipment for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG spent CHF0 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Carl Zeiss Meditec AG's sale of property, plant, equipment for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG gained CHF0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Carl Zeiss Meditec AG's purchase of business for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG spent CHF0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Carl Zeiss Meditec AG's sale of business for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG gained CHF0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Carl Zeiss Meditec AG's purchase of investment for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG spent {stock_data.stock.currency_symbol}}0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Carl Zeiss Meditec AG's sale of investment for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG gained CHF0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Carl Zeiss Meditec AG's net Intangibles purchase and sale for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG paid CHF0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Carl Zeiss Meditec AG's cash from discontinued investing activities for the three months ended in Dec. 2025 was 0 Mil. It means Carl Zeiss Meditec AG paid CHF0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Carl Zeiss Meditec AG's cash from other investing activities for the three months ended in Dec. 2025 was CHF0 Mil. It means Carl Zeiss Meditec AG paid CHF0 Mil for other investing activities.


Carl Zeiss Meditec AG Cash Flow from Investing Related Terms


Carl Zeiss Meditec AG Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cash Flow from Investing Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.64 -89.51 -106.55 -387.69 -85.06

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.43 2.02 21.94 -92.44 0.65
XSWX:AFX
75GF Score
Carl Zeiss Meditec AG XSWX:AFX
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Carl Zeiss Meditec AG's Cash Flow from Investing for the fiscal year that ended in Sep. 2025 is calculated as:

Carl Zeiss Meditec AG's Cash Flow from Investing for the quarter that ended in Dec. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of CHF-68 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Cash Flow from Investing of CHF-68 Mil as of Dec. 2025. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cash Flow from Investing too high?
Carl Zeiss Meditec AG's current Cash Flow from Investing is CHF-68 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cash Flow from Investing compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cash Flow from Investing of CHF-68 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Medical Devices & Instruments company?
A good Cash Flow from Investing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cash Flow from Investing is CHF-68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XSWX:AFX) has a current Cash Flow from Investing of CHF-68 Mil. The stock's GF Value™ is CHF68.89, compared to a current price of CHF29.80 — trading 56.7% below its estimated fair value. The current Cash Flow from Investing is CHF-68 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Cash Flow from Investing is CHF-68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF29.80 is trading 56.7% below its estimated GF Value™ of CHF68.89.

Key valuation signals for XSWX:AFX:

  • Cash Flow from Investing: CHF-68 Mil
  • GF Value™: CHF68.89 vs. price of CHF29.80 (56.7% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
75GF Score

Get the complete analysis for XSWX:AFX

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF29.80
Price
CHF68.89
GF Value